ERBB2 and neoplasm: Furthermore, the molecular tumor subtypes luminal A, luminal B HER2-negative, luminal B HER2-positive, HER2-enriched, and triple-negative accounted for 33.82%, 27.94%, 19.12%, 5.88%, and 13.24% of the patients, respectively.